Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMK8AQP)

Drug Name
Sirukumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Cutaneous lupus erythematosus EB5Z Phase 3 [1]
Giant cell arteritis 4A44.2 Phase 3 [2]
Rheumatoid arthritis FA20 Phase 3 [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Major depressive disorder 6A70.3 Phase 2 [5]
Cross-matching ID
TTD Drug ID
DMK8AQP

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 6 receptor (IL6R) TT0E5SK IL6RA_HUMAN; IL6RB_HUMAN Not Available [6]
Interleukin-6 (IL6) TTT1V78 IL6_HUMAN Inhibitor [2]
HUMAN interleukin 6 (IL6) TTJH4Y5 IL6_HUMAN Inhibitor [7]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-6 (IL6) DTT IL6 5.133 5.921 4.797 7.627
Interleukin 6 receptor (IL6R) DTT IL6R 6.42 5.564 5.031 5.404
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Cutaneous lupus erythematosus
ICD Disease Classification EB5Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 6 receptor (IL6R) DTT IL6R; IL6ST 1.13E-04 1.32 1.28
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01856309) Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01689532) A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine. U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT04380961) A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19. U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
7 Sirukumab: A Potential Treatment for Mood Disorders Adv Ther. 2017 Jan;34(1):78-90.